



Resistenza agli antibiotici in ambito umano e veterinario. Due facce della stessa medaglia?

Enrico Ricchizzi

*Area Rischio Infettivo
ASSR Emilia-Romagna*

Ferrara 10 Novembre 2016

How does antibiotic resistance spread?

Antibiotic resistance is the ability of bacteria to combat the action of one or more antibiotics. Humans and animals do not become resistant to antibiotic treatments, but bacteria carried by humans and animals can.



1 Animals may be treated with antibiotics and they can therefore carry antibiotic-resistant bacteria. **2** Vegetables may be contaminated with antibiotic-resistant bacteria from animal manure used as fertilizer. **3** Antibiotic-resistant bacteria can spread to humans through food and direct contact with animals.

In animal farming

4 Humans sometimes receive antibiotics prescribed to treat infections. However, bacteria develop resistance to antibiotics as a natural, adaptive reaction. Antibiotic-resistant bacteria can then spread from the treated patient to other persons.

In the community


5 Humans may receive antibiotics in hospitals and then carry antibiotic-resistant bacteria. These can spread to other patients via unclean hands or contaminated objects. **6** Patients who may be carrying antibiotic-resistant bacteria will ultimately be sent home, and can spread these resistant bacteria to other persons.

In healthcare facilities

7 Travellers requiring hospital care while visiting a country with a high prevalence of antibiotic resistance may return with antibiotic-resistant bacteria.


8 Even if not in contact with healthcare, travellers may carry and import resistant bacteria acquired from food or the environment during travel.

Through travel





Introduzione degli antibiotici nella pratica clinica



Note: Some of the dates are estimates only.

From: Pray L (Antibiotic R&D, Cambridge Healthcare Institute, Needham, MA, 2008).

Comparsa della Resistenza

Antibiotico resistenza: i concetti base

Esposizione


Selezione

Espansione

Susceptible population


resistant clones

spread



Uso di antibiotici in ambito territoriale - ESAC-Net 2012

Medicina umana



ITALIA: consumi elevati e uso frequente di antibiotici ad ampio spettro (Es. chinoloni e cefalosporine)

Escherichia coli R - Cefalosporine III gen.





Figure 5.11. *Escherichia coli*:

...tion cephalosporins in 2005.

ESBL




Figure 5.14. *Escherichia coli*: proportion of invasive isolates with resistance to third generation cephalosporins in 2008.

* These countries did not report any data or reported less than 10 isolates.



Fonte - EARS-Net



Klebsiella pneumoniae

R - CEF III Gen




Figure 4.22. *Klebsiella pneumoniae*: proportion of invasive isolates resistant to third generation cephalosporins in 2005.





Figure 5.23. *Klebsiella pneumoniae*: proportion of invasive isolates resistant to 3rd generation cephalosporins in 2006.

Figure 3.7. *Klebsiella pneumoniae*. Percentage (%) of invasive isolates with resistance to third-generation cephalosporins, by country, EU/EEA countries, 2013




ESBL

Fonte - EARS-Net





CARBAPENEMI



- Antibiotici β -lattamici ad ampio spettro efficaci nei confronti di un'ampia varietà di famiglie di microrganismi

- Nella pratica clinica i carbapenemici sono considerati* gli antibiotici «risolutivi» per il trattamento di infezioni gravi, tipicamente nel paziente ospedalizzato

	Streptococcus & MSSA	Entero-bacteriaeae	Gram (-) non fermentanti	Anaerobi
Imipenem	+	+	+	+
Meropenem	+	+	+	+
Ertapenem	+	+	Attività limitata	+
Doripenem	+	+	+	+

* forse "erano"...

Enterobacteriaceae produttori di carbapenemasi

NDM-1



Origin and spread of *NDM-1*

The NDM-1 enzyme was named after *New Delhi*, the capital city of *India*, as it was first described by Yong et al. in December 2009 in a Swedish national who fell ill with an antibiotic-resistant bacterial infection that he acquired in India.^[12] The infection was unsuccessfully treated in a New Delhi hospital, and, after the patient's repatriation to Sweden, a carbapenem-resistant *Klebsiella pneumoniae* strain bearing the novel gene was identified

Turismo per Chirurgia estetica low cost

Klebsiella pneumoniae

Resistenza ai CARBAPENEMI

Figure 5.25: *Klebsiella pneumoniae*: proportion of invasive isolates resistant to carbapenems in 2009



Figure 5.25: *Klebsiella pneumoniae*: proportion of invasive isolates resistant to carbapenems in 2010





Figure 4.12: *Klebsiella pneumoniae*: percentage (%) of invasive isolates with resistance to carbapenems, by country, EU/EEA countries, 2011



Enterobatteri produttori di CARBAPENEMASI
CPE

Fonte - EARS-Net



Come trattare le infezioni da CPE?

- Efficacia dei trattamenti con
MEROPENEM + TIGECICLINA + COLISTINA
OPPURE
- **Ceftazidime** (Cefalosporina III gen.)
+
Avybactam (inibitore di eSBL e *alcune* Carbapenemasi es. KPC)

È la strada giusta?



THE LANCET Infectious Diseases

Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study

Yi-Yun Liu*, Yang Wang*, Timothy R Walsh, Ling-Xian Yi, Rong Zhang, James Spencer, Yohei Doi, Guobao Tian, Baolei Dong, Xianhui Huang, Lin-Feng Yu, Danxia Gu, Hongwei Ren, Xiaojie Chen, Luchao Lv, Dandan He, Hongwei Zhou, Zisen Liang, Jian-Hua Liu, Jianzhong Shen

Gene della Resistenza a Colistina mediata da Plasmide in Escherichia coli e Klebsiella pneumoniae

27 Maggio 2016

Allarme negli Usa, donna colpita da batterio resistente a tutti gli antibiotici

Per la prima volta, alcuni ricercatori hanno trovato una persona portatrice di un batterio con un gene che lo rende resistente persino ai trattamenti più potenti






J Antimicrob Chemother 2016
doi:10.1093/jac/dkw195
Advance Access publication 3 June 2016

Emergence of the colistin resistance *mcr-1* determinant in commensal *Escherichia coli* from residents of long-term-care facilities in Italy

Maria Giufrè, Monica Monaco, Marisa Accogli, Annalisa Pantosti and Marina Cerquetti* on behalf of the PAMURSA Study Group†

Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy

*Ospiti di Strutture residenziali per anziani colonizzati da *Escherichia coli* eSBL e MCR-1*



Quale futuro?

Escherichia coli – EARS-Net 2013

R - Carbapenemi



Quale futuro?



18 Novembre

EUROPEAN ANTIBIOTIC AWARENESS DAY



A European Health Initiative



<http://ecdc.europa.eu/it/eaad/Pages/Home.aspx>



#EAAD